`
`
`
`
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`ELI LILLY AND COMPANY
`Petitioner,
`
`v.
`
`TEVA PHARMACEUTICALS INTERNATIONAL GMBH
`Patent Owner.
`
`_____________________
`
`Case IPR2018-01710
`U.S. Patent No. 8,586,045
`_____________________
`
`TEVA PHARMACEUTICALS INTERNATIONAL GMBH’S
`UPDATED EXHIBIT LIST
`
`
`
`
`
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2001
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`2011
`
`Description
`Edvinsson, L., “Calcitonin Gene-Related Peptide (CGRP) in
`Cerebrovascular Disease,” TheScientificWorldJOURNAL, 2:1484-90
`(2002)
`Hasbak, P., et al., “Investigation of CGRP Receptors and Peptide
`Pharmacology in Human Coronary Arteries. Characterization with a
`Nonpeptide Antagonist,” The Journal of Pharmacology and
`Experimental Therapeutics, 304:326-33 (2003)
`Brain, S. and Grant, A., “Vascular Actions of Calcitonin
`Gene-Related Peptide and Adrenomedullin,” Physiol Rev., 84:903-34
`(2004)
`Chiba, T., et al., “Calcitonin gene-related peptide receptor antagonist
`human CGRP-(8-37),” Am. J. Physiol.:Endocrin. & Metab.,
`19:E331-35 (1989)
`File History for U.S. Patent No. 8,597,649 B2
`Gegg, Jr., C., et al., “CGRP Peptide Antagonists And
`Conjugates,” U.S. Patent No. 8,168,592 B2 (filed October 19, 2006;
`issued May 1, 2012)
`Escott, K. and Brain, S., “Effect of a calcitonin gene-related peptide
`antagonist (CGRP8-37) on skin vasodilatation and oedema induced by
`stimulation of the rat saphenous nerve,” Br. J. Pharmacol.
`110:772-76 (1993)
`Rist, B., et al., “CGRP 27-37 analogues with high affinity to the
`CGRP1 receptor show antagonistic properties in a rat blood flow
`assay,” Regul. Pept. 79:153-58 (1999)
`Edvinsson, L., "Blockade of CGRP receptors in the intracranial
`vasculature: a new target in the treatment of headache," Cephalalgia,
`24:611-22 (2004)
`Goadsby, P., “Calcitonin Gene-Related Peptide Antagonists as
`Treatments of Migraine and Other Primary Headaches,” Drugs,
`65:2557-67 (2005)
`Supowit, S., et al., “Calcitonin Gene-Related Peptide Protects
`Against Hypertension-Induced Heart and Kidney Damage,”
`Hypertension, 45:109-14 (2005)
`
`- 2 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2012
`
`2013
`
`2014
`
`2015
`
`2016
`
`2017
`
`2018
`
`2019
`
`2020
`
`2021
`
`Description
`Aiyar, N., et al., “Pharmacology of SB-273779, a Nonpeptide
`Calcitonin Gene-Related Peptide 1 Receptor Antagonist,” The
`Journal of Pharmacology and Experimental Therapeutics,
`296:768-75 (2001)
`Rudolf, K., et al., “Modified Aminoacids, Pharmaceuticals
`Containing These Compounds and Method for Their Production,”
`U.S. Patent Application Publication No. 2003/0069231 A1 (filed
`April 10, 2002; published April 10, 2003)
`Patchett, A., et al., “Benzimidazolinyl Piperidines as CGRP
`Ligands,” U.S. Patent No. 6,552,043 B1 (filed September 22, 1999;
`issued April 22, 2003)
`Zimmer, O., et al., “Substituted Cyclopentene Compounds,” U.S.
`Patent No. 7,109,214 B2 (filed November 19, 2004; issued
`September 19, 2006)
`Chaturvedula, P., et al., “Constrained Compounds as
`CGRP-Receptor Antagonists,” U.S. Patent No. 7,384,930 B2 (filed
`October 11, 2005; issued June 10, 2008)
`Rudolf, K., et al., “Modified Aminoacids, Pharmaceuticals
`Containing These Compounds and Method for Their Production,”
`U.S. Patent No. 6,344,449 B1 (filed September 8, 1997; issued
`February 5, 2002)
`Paone, D., et al., “CGRP Receptor Antagonists,” U.S. Patent No.
`7,772,224 B2 (filed April 3, 2009; issued August 10, 2010)
`Petersen, K., et al., “The CGRP-antagonist, BIBN4096BS does not
`affect cerebral or systemic haemodynamics in healthy volunteers,”
`Cephalalgia, 25:139-47 (2004)
`Leahy, D., et al., “Process For The Preparation of
`Cycloheptapyridine CGRP Receptor Antagonists,” U.S. Patent No.
`8,669,368 B2 (filed September 19, 2011; issued March 11, 2014)
`Clinical Trials for BIBN4096BS, downloaded from
`https://clinicaltrials.gov/ct2/results?cond=&term=bibn4096bs&cntry
`=&state=&city=&dist (last accessed November 5, 2018)
`
`- 3 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2022
`
`2023
`
`2024
`
`2025
`
`2026
`
`2027
`
`2028
`
`2029
`
`2030
`
`2031
`
`Description
`Clinical Trials for MK-0974, downloaded from
`https://clinicaltrials.gov/ct2/results?cond=&term=mk-0974&cntry=
`&state=&city=&dist (last accessed on November 15, 2018)
`Clinical Trials for BMS-927711, downloaded from
`https://clinicaltrials.gov/ct2/results?cond=&term=BMS-927711&cnt
`ry=&state=&city=&dist (last accessed on November 5, 2018)
`Zeller, J., et al., “Antagonist Antibodies Directed Against Calcitonin
`Gene-Related Peptide and Methods Using Same,” U.S. Patent No.
`8,007,794 B2 (filed November 2, 2006; issued August 30, 2011)
`Zeller, J., et al., “Antagonist Antibodies Directed Against Calcitonin
`Gene-Related Peptide and Methods Using Same,” U.S. Patent No.
`8,597,649 B2 (filed April 25, 2013; issued December 3, 2013)
`Zeller, J., et al., "Antagonist Antibodies Directed Against Calcitonin
`Gene-Related Peptide and Methods Using Same," U.S. Patent No.
`9,340,614 B2 (filed August 31, 2015; issued May 17, 2016)
`Zeller, J., et al., "Antagonist Antibodies Directed Against Calcitonin
`Gene-Related Peptide and Methods Using Same," U.S. Patent No.
`9,266,951 B2 (filed August 31, 2015; issued February 23, 2016)
`Zeller, J., et al., "Antagonist Antibodies Directed Against Calcitonin
`Gene-Related Peptide and Methods Using Same," U.S. Patent No.
`9,346,881 B2 (filed August 31, 2015; issued May 24, 2016)
`Zeller, J., et al., "Antagonist Antibodies Directed Against Calcitonin
`Gene-Related Peptide," U.S. Patent No. 9,890,210 B2 (filed May 5,
`2017; issued February 13, 2018)
`Zeller, J., et al., "Antagonist Antibodies Directed Against Calcitonin
`Gene-Related Peptide," U.S. Patent No. 9,890,211 B2 (filed May 5,
`2017; issued February 13, 2018)
`Zeller, J., et al., "Methods for Treating Headache Using Antagonist
`Antibodies Directed Against Calcitonin Gene-Related Peptide," U.S.
`Patent No. 9,884,907 B2 (filed May 5, 2017; issued February 6,
`2018)
`
`- 4 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2032
`
`2033
`2034
`2035
`2036
`2037
`2038
`2039
`2040
`2041
`2042
`2043
`2044
`2045
`
`2046
`
`2047
`
`2048
`
`2049
`2050
`2051
`
`2052
`
`Description
`Zeller, J., et al., "Methods for Treating Headache Using Antagonist
`Antibodies Directed Against Calcitonin Gene-Related Peptide," U.S.
`Patent No. 9,884,908 B2 (filed May 5, 2017; issued February 6,
`2018)
`File History for U.S. Patent No. 8,007,794 B2
`File History for U.S. Patent No. 8,586,045 B2
`File History for U.S. Patent No. 8,734,802 B1
`File History for U.S. Patent No. 9,115,194 B2
`File History for U.S. Patent No. 9,328,168 B2
`File History for U.S. Patent No. 9,346,881 B2
`File History for U.S. Patent No. 9,266,951 B2
`File History for U.S. Patent No. 9,340,614 B2
`File History for U.S. Patent No. 9,365,648 B1
`File History for U.S. Patent No. 9,890,211 B2
`File History for U.S. Patent No. 9,890,210 B2
`File History for U.S. Patent No. 9,884,907 B2
`File History for U.S. Patent No. 9,884,908 B2
`Clinical Trials for BHV-3000, downloaded from
`https://clinicaltrials.gov/ct2/results?cond=&term=bhv-3000&cntry=
`&state=&city=&dist (last accessed on November 5, 2018)
`Alberts, B., et al., Molecular Biology of the Cell, p. G:34, 4th ed.,
`Garland Science, Taylor & Francis Group, New York (2002)
`John H. Byrne, Essential Medical Physiology, Chapter 6:
`Neuromuscular and Synaptic Transmission, pp. 97-122, (Leonard R.
`Johnson, ed.), 3rd Ed., Elsevier Academic Press, Amsterdam (2003)
`Intentionally left blank
`Intentionally left blank
`Intentionally left blank
`Inman, S., “Anti-CGRP Monoclonal Antibodies Transforming
`Migraine Treatment,” (Oct. 22, 2018), NeurologyLive
`https://www.neurologylive.com/conferences/ana-2018/anticgrp-mon
`oclonal-antibodies-transforming-migraine-treatment, (last visited
`May 20, 2019)
`
`- 5 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`2053
`2054
`2055
`
`2056
`
`2057
`
`2058
`
`2059
`
`2060
`
`2061
`
`2062
`
`2063
`
`2064
`
`2065
`
`Description
`“Pain Like No Other,” UCLA Health David Geffen School of
`Medicine 38(2): 18-25 (2018)
`Intentionally left blank
`Curriculum Vitae of Steven M. Foord, Ph.D.
`Hay, D.L., et al., “A comparison of the actions of BIBN4096BS and
`CGRP8-37 on CGRP and adrenomedullin receptors expressed on
`SK-N-MC, L6, Col 29 and Rat 2 cells,” British Journal of
`Pharmacology 137(1): 80-86 (2002)
`Hay, D.L., et al., “CL/RAMP2 and CL/RAMP3 produce
`pharmacologically distinct adrenomedullin receptors: a comparison
`of effects of adrenomedullin22–52, CGRP8–37 and BIBN4096BS,”
`British Journal of Pharmacology 140(3): 477-486 (2003)
`Uren, N.G., et al., “Effect of intravenous calcitonin gene related
`peptide on ischaemia threshold and coronary stenosis severity in
`humans,” Cardiovascular Research 27: 1477-1481 (1993)
`Geppetti, P., et al., “CGRP and migraine: neurogenic inflammation
`revisited,” Journal of Headache & Pain 6(2):61-70 (2005)
`Hay, D., et al., “Pharmacological discrimination of calcitonin
`receptor: receptor Activity-modifying protein complexes,”
`Molecular Pharmacology 67(5): 1655-1665 (2005)
`Franco-Cereceda, A. and Liska, J., “Potential of Calcitonin
`Gene-Related Peptide in Coronary Heart Disease,” Pharmacology
`60:1-8 (2000)
`The Biochemical Basis of Neuropharmacology, Chapter 4:
`Receptors, 65-84, (Jack R. Cooper et al. eds., 8th ed. 2003)
`Rang, H., et al., Pharmacology, p. 15, 5th ed., Elsevier Science
`Limited, (2003)
`Molecular Cell Biology, Chapter 13: Signaling molecules and
`cell-surface receptors, 537-538, (Harvey Lodish et al. eds., 5th ed.
`2003)
`Sheykhzade, M., et al., “Noncompetitive antagonism of
`BIBN4096BS on CGRP-induced responses in human subcutaneous
`arteries,” British Journal of Pharmacology 143(8): 1066-1073 (2004)
`
`- 6 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2066
`
`2067
`
`2068
`
`2069
`
`2070
`
`2071
`
`2072
`
`2073
`
`2074
`2075
`2076
`
`2077
`
`2078
`
`Description
`Gallai, V., et al., “Vasoactive peptide levels in the plasma of young
`migraine patients with and without aura assessed both interictally and
`ictally,” Cephalalgia 15(1):384-390 (1995)
`Sarchielli, P., et al., “Nitric oxide metabolites, prostaglandins
`and trigeminal vasoactive peptides in internal jugular vein
`blood during spontaneous migraine attacks,” Cephalalgia,
`20(10): 907-918 (2000)
`Hay, D.L. and Poyner, D. “The Preclinical Pharmacology
`of BIBN4096BS, a CGRP Antagonist,” Cardiovascular Drug
`Reviews 23(1): 31-42 (2005)
`Intentionally left blank
`Wimalawansa, S.J., “Circadian variation of plasma calcitonin
`gene-related peptide in man,” Journal of Neuroendocrinology 3(3):
`319-322 (1991)
`Burgey, C., et al., “CGRP Receptor Antagonists,” PCT International
`Publication No. WO 2004/092166 (filed April 9, 2004; published
`October 28, 2004)
`Intentionally left blank
`Hendrikse, E.R., et al., “Molecular studies of CGRP and the CGRP
`family of peptides in the central nervous system,” Cephalalgia 39(3):
`403-419 (2019)
`Intentionally left blank
`Concise Dictionary of Biomedicine and Molecular Biology, pp. 40,
`80 (Juo, P-S., ed.)
` Intentionally left blank
`Jain, R., “Physiological barriers to delivery of monoclonal antibodies
`and other macromolecules in tumors,” Cancer Research (Suppl.) 50:
`814s-819s (1990)
`Juul, R., et al., “Calcitonin gene-related peptide-LI in subarachnoid
`haemorrhage in man. Signs of activation of the
`trigemino-cerebrovascular system?,” Br. J. Neurosurgery 4: 171-180
`(1990)
`
`- 7 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2079
`
`2080
`2081
`2082
`2083
`
`2084
`
`2085
`
`2086
`2087
`
`2088
`
`2089
`
`2090
`
`2091
`
`2092
`
`Description
`Gennari, C., et al., “Improved cardiac performance with human
`calcitonin gene related peptide in patients with congestive heart
`failure,” Cardiovascular Research 24: 239-241 (1990)
`Intentionally left blank
`Intentionally left blank
`Humbert, M., et al., “Treatment of pulmonary arterial hypertension,”
`N. Engl. J. Med. 351:1425-1436 (2004)
`Intentionally left blank
`Tjen-A-Looi, S., et al., “CGRP and somatostatin modulate chronic
`hypoxic pulmonary hypertension,” Am. J. Physiol. 263(3):
`H681-H690 (1992)
`Sagonowsky, E., “Amgen's quick Aimovig launch boosts blockbuster
`hopes for Lilly, Teva and Alder: analyst,” (Aug. 20, 2018) Fierce
`Pharma,
`https://www.fiercepharma.com/pharma/amgen-s-quick-aimovig-lau
`nch-has-implications-for-lilly-teva-and-alder-analyst, (last visited
`May 29, 2019)
`Parnetti, L., et al., “Headache and ischemic stroke,” J. Headache
`Pain 3(1):15-20 (2002)
`Intentionally left blank
`Etminan, M., et al., “Risk of ischaemic stroke in people with
`migraine: systematic review and meta-analysis of observational
`studies,” Brit. Med. J. 330: 63-65 (2005)
`Wimalawansa, S.J., “Age-related changes in tissue contents of
`immunoreactive calcitonin gene-related peptide,” Aging Clin. Exp.
`Res. 4(1): 211-217 (1992)
`David J. King, Applications and Engineering of Monoclonal
`Antibodies, Chapters 1-3 (1998)
`An, Z., “Monoclonal antibodies – a proven and rapidly
`expanding therapeutic modality for human diseases,” Protein Cell
`1(4): 319-330 (2010)
`Alberts, B., et al., Molecular Biology of the Cell, pp. 1363-1422, 4th
`ed., Garland Science, Taylor & Francis Group, New York (2002)
`
`- 8 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2093
`
`2094
`
`2095
`
`2096
`
`2097
`
`2098
`
`2099
`
`2100
`
`2101
`
`2102
`
`2103
`
`2104
`
`Description
`Köhler, G. and Milstein, C., “Continuous cultures of fused cells
`secreting antibody of predefined specificity,” Nature 256(5517):
`495-497 (1975)
`Berger, M., et al., “Therapeutic Applications of Monoclonal
`Antibodies,” Am. J. Med. Sci. 324(1):14-30 (2002)
`Siberil, S. and Teillaud, J., Antibodies Volume 2: Novel
`Technologies and Therapeutic Use, Chapter 12: Future Prospects In
`Antibody Engineering And Therapy, pp. 199-215 (G. Subramanian,
`ed., Kluwer Academic/Plenum Publishers, New York (2004))
`Daugherty, A.L. and Mrsny, R.J., “Formulation and delivery issues
`for monoclonal antibody therapeutics,” Advanced Drug Delivery
`Reviews 58(5-6): 686-706 (2006)
`Lonberg, N., “Human antibodies from transgenic animals,” Nature
`Biotechnology 23(9): 1117-1125 (2005)
`Presta, L.G., “Engineering of therapeutic antibodies to minimize
`immunogenicity and optimize function,” Advanced Drug Delivery
`Reviews 58(5-6): 640-656 (2006)
`Winter, G., and Harris, W.J., “Humanized antibodies,” Trends in
`Pharmacological Sciences 14(5): 139-143 (1993)
`Caldas, C., et al., “Humanization of the anti-CD18 antibody 6.7: an
`unexpected effect of a framework residue in binding to antigen,”
`Molecular Immunology 39(15): 941-952 (2003)
`Vaughan, T.J., et al., “Human antibodies by design,” Nat. Biotechnol.
`16(6): 535-539 (1998)
`Van Dijk, M.A., and Van de Winkel, J.G.J., “Human antibodies as
`next generation therapeutics,” Current Opinion in Chemical Biology
`5(4):368-374 (2001)
`Jacobovits, A., “The long-awaited magic bullets:
`therapeutic human monoclonal antibodies from transgenic mice,”
`Exp. Opin. Invest. Drugs 7(4):607-614 (1998)
`Conflict of Interest in Medical Research, Education and Practice, Lo,
`B. and Field, M.J., eds., pp.1-414, The National Academies Press,
`Washington, D.C. (2009)
`
`- 9 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`2105
`
`2106
`
`2107
`
`2108
`
`2109
`
`2110
`
`2111
`
`2112
`
`2113
`
`2114
`
`2115
`
`Description
`Bains, W., “Failure rates in drug discovery and development:
`will we ever get any better?,” Drug Discovery World 9-18 (2004)
`Hoogenboom, H., et al., “Production of Chimeric Antibodies - A
`Combinatorial Approach,” U.S. Patent No. 5,565,332 (filed
`September 23, 1992; issued October 15, 1996)
`Stockwin, L.H. and Holmes, S., “The role of therapeutic antibodies in
`drug discovery,” Biochemical Society Transactions 31(2): 433-436
`(2003)
`Ravandi, F., et al., “Modulation of Cellular Signaling Pathways:
`Prospects for Targeted Therapy in Hematological Malignancies,”
`Clinical Cancer Research 9(2): 535-550 (2003)
`European Medicines Agency Guideline On Strategies To Identify
`And Mitigate Risks For First-Inhuman Clinical Trials With
`Investigational Medicinal Products July 2007
`Janssens, N., et al., “The Wnt-dependent signaling pathways as target
`in oncology drug discovery,” Investigational New Drugs 24(4):
`263-280 (2006)
`British National Formulary, pp.435-470, Vol. 52, BMJ Publishing
`Group Ltd and RPS Publishing (2006)
`Knauf, M.J., et al., “Relationship of Effective Molecular Size to
`Systemic Clearance in Rats of Recombinant Interleukin-2
`Chemically Modified with Water-soluble Polymers,” J. Biol. Chem.
`263(29): 15064-15070 (1988)
`Chapman, A.P., et al., “Therapeutic antibody fragments with
`prolonged in vivo half-lives,” Nature Biotechnology 17(8): 780-783
`(1999)
`Murray, J.L., “Monoclonal Antibody Treatment of Solid Tumors:
`A Coming of Age,” Seminars in Oncology 27(6 suppl. 11): 64-70
`(2000)
`Fujimori, K., et al., “Modeling Analysis of the Global and
`Microscopic Distribution of Immunoglobulin G, F(ab’)2, and Fab in
`Tumors,” Cancer Research 49(20): 5656-5663 (1989)
`
`- 10 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2116
`
`2117
`
`2118
`
`2119
`
`2120
`
`2121
`
`2122
`2123
`
`2124
`
`2125
`
`2126
`
`2127
`
`2128
`
`Description
`Leveque, D., et al., “Pharmacokinetics of Therapeutic Monoclonal
`Antibodies Used in Oncology,” Anticancer Research 25(3C):
`2327-2343 (2005)
`Maraschiello, C., “The Relevance of Immunogenicity in Preclinical
`Development,” J. Bioanal. Biomed. 6:1-4 (2014)
`Hamuro, L., et al., “Perspectives on Subcutaneous Route of
`Administration as an Immunogenicity Risk Factor for Therapeutic
`Proteins,” J. Pharm. Sci., 106: 2946-2954 (2017)
`Schunk, M.K. and Macullum, G.E., “Applications and Optimization
`of Immunization Procedures,” ILAR Journal 46(3): 241-257 (2005)
`Fallowfield, L., et al., “ Patients’ preference for administration of
`endocrine treatments by injection or tablets: results from
`a study of women with breast cancer,” Annals of Oncology 17(2):
`205-210 (2006)
`Chowdhury, P.S. and Wu, H., “Tailor-made antibody therapeutics,”
`Methods 36(1): 11-24 (2005)
`Oh-hashi, Y., et al., “Elevated Sympathetic Nervous Activity in Mice
`Deficient in αCGRP,” Circ. Res. 89(11):983-990 (2001)
`Intentionally left blank
`Wimalawansa, S.J., “Age-Related Increase of Calcitonin
`Gene-Related Peptide in Rat Thyroid and Circulation,” Peptides
`12(5): 1143-1147 (1991)
`Gangula, P.R.R., et al., “Increased Blood Pressure in α-Calcitonin
`Gene–Related Peptide/Calcitonin Gene Knockout Mice,”
`Hypertension 35(part 2): 470-475 (2000)
`The Seventh Report of the Joint National Committee on Prevention,
`Detection, Evaluation, and Treatment of High Blood Pressure
`(August 2004)
`“Hypertension in America: A National Reading,” Am. J. Manag.
`Care 11(suppl. 13): S383-S385 (2005)
`Ferrara, N., “VEGF as a Therapeutic Target in Cancer,” Oncology
`69(suppl. 3):11-16 (2005)
`
`- 11 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2129
`
`2130
`
`2131
`
`2132
`
`2133
`
`2134
`
`2135
`
`2136
`
`2137
`2138
`
`2139
`
`Description
`Yotsumoto, F., et al., “Efficacy of Ligand-based Targeting
`for the EGF System in Cancer,” Anticancer Research 29: 4879-4885
`(2009)
`Zeller, J., et al., “CGRP function-blocking antibodies inhibit
`neurogenic vasodilatation without affecting heart rate or arterial
`blood pressure in the rat,” Brit. J. Pharmacol. 155: 1093-1103 (2008)
`Therapeutic Antibody Engineering, Chapter 12: Antibody fragments,
`265-297 (William Strohl and Lila Strohl, No. 11, 2012)
`Wertheimer, A., et al., “Too Many Drugs? The Clinical And
`Economic Value Of Incremental Innovations,” Investing in Health:
`The Social and Economic Benefits of Health Care Innovation 14:
`77-118 (2001)
`Watkins, B.A., et al., “Resistance of Human Immunodeficiency
`Virus Type 1 to Neutralization by Natural Antisera Occurs through
`Single Amino Acid Substitutions That Cause Changes in Antibody
`Binding at Multiple Sites,” Journal of Virology 70(12): 8431-8437
`(1996)
`Tulip, W.R., et al., “Crystal Structures of two Mutant
`Neuraminidase-Antibody Complexes with Amino Acid Substitutions
`in the Interface,” J. Mol. Biol. 227(1): 149-159 (1992)
`Goldberg, M.E., and Djavadi-Ohaniance, L., “Methods for
`measurement of antibody/antigen affinity based on ELISA and RIA,”
`Current Opinion in Immunology 5(2): 278-281 (1993)
`Praither, J.D., “Basic Principles of Radioimmunoassay Testing:
`A Simple Approach,” Journal of Nuclear Medicine Technology
`13(1): 34-43 (1985)
`Intentionally left blank
`Curriculum Vitae of Ian M. Tomlinson, M.A., Ph.D.
`Juul, R., et al., “Calcitonin gene-related peptide (human α-CGRP)
`counteracts vasoconstriction in human subarachnoid haemorrhage,”
`Neuroscience Letters 170(1) : 67-70 (1994)
`
`- 12 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2140
`
`2141
`2142
`
`2143
`
`2144
`
`2145
`
`2146
`
`2147
`
`2148
`
`2149
`
`2150
`
`2151
`
`2152
`
`Description
`Christopoulos, G., et al., “Multiple Amylin Receptors Arise from
`Receptor Activity Modifying Protein Interaction with the Calcitonin
`Receptor Gene Product,” Molecular Pharmacology, 56(1):235-242
`(1999)
`Intentionally left blank
`Curriculum Vitae of Michel D. Ferrari, M.D., Ph.D.
`Collard, C.D. and Gelman, S., “Pathophysiology, Clinical
`Manifestations, and Prevention of Ischemia–Reperfusion Injury,”
`Anesthesiology 94(6): 1133-1138 (2001)
`Solenski, N.J., “Transient Ischemic Attacks: Part I. Diagnosis and
`Evaluation,” Am Fam Physician 69(7): 1665-74 (2004)
`Fox, K., et al., “Guidelines on the management of stable angina
`pectoris,” European Heart Journal 27: 1341-1381 (2006)
`Panza, J.A., “Myocardial Ischemia and the Pains of the Heart,” New
`Engl. J. Med. 346(25): 1934-1935 (2002)
`Parker, J.O., “Angina Pectoris: A Review of Current and Emerging
`Therapies,” Am. J. Manag. Care 10(suppl. 11): S332-338 (2004)
`Sobey, C.G. and Faraci, F.M., “Subarachnoid Haemorrhage: What
`Happens To The Cerebral Arteries?,” Clinical and Experimental
`Pharmacology and Physiology 25(11): 867-876 (1998)
`Preibisz, J.J., “Calcitonin Gene-Related Peptide and Regulation of
`Human Cardiovascular Homeostasis,” Am. J. Hypertens.
`6(5 pt. 1): 434-450 (1993)
`Kallner, G. and Franco-Cereceda, A., “Aggravation of Myocardial
`Infarction in the Porcine Heart by Capsaicin-Induced Depletion of
`Calcitonin Gene-Related Peptide (CGRP),” Journal of
`Cardiovascular Pharmacology 32(3): 500-504 (1998)
`Mair, J., et al., “Plasma CGRP in acute myocardial infarction,”
`Lancet 335: 168 (1990)
`Li, Y-J., et al., “Calcitonin gene-related peptide-induced
`preconditioning protects against ischemia-reperfusion injury in
`isolated rat hearts,” Eur. J. Pharmacol. 311(2-3): 163-167 (1996)
`
`- 13 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2153
`
`2154
`
`2155
`
`2156
`
`2157
`
`2158
`
`2159
`
`2160
`
`2161
`
`2162
`
`2163
`
`Description
`Weintraub, A., “Teva abandons Ajovy's cluster headache ambitions,
`clearing a path for Lilly to forge a new market,” (April 24, 2019),
`Fierce Pharma,
`https://www.fiercepharma.com/pharma/teva-ditches-trial-ajovy-clus
`ter-headache-clearing-a-path-for-lilly-to-forge-a-new-market, (last
`visited May 29, 2019)
`Edvinsson, L., et al., “Reduced levels of calcitonin gene-related
`peptide-like immunoreactivity in human brain vessels after
`subarachnoid haemorrhage,” Neuroscience Letters 121: 151-154
`(1991)
`Edvinsson, L. and Uddmann, R., “Neurobiology in primary
`headaches,” Brain Research Reviews 48: 438-456 (2005)
`Shawket, S.A. and Brown, M., “Pathogenic and Therapeutic
`Implications of Calcitonin-Gene-Related Peptide in the
`Cardiovascular System,” Trends Cardiovasc. Med. 1(5): 211-215
`(1991)
`Bousser, M.G. and Welch, K.M.A., “Relation between migraine and
`stroke,” Lancet Neurol. 4(9): 533-42 (2005)
`Carolei, A., et al., “Comorbidities of migraine: a user-friendly
`overview,” J. Headache Pain 4(suppl. 1): S23-S25 (2003)
`Stang, P.E., et al., “Headache, cerebrovascular symptoms, and stroke
`The Atherosclerosis Risk in Communities Study,” Neurology 64(9):
`1573-1577 (2005)
`Curriculum Vitae of Alan M. Rapoport, M.D.
`Dodick, D.W., et al., “Safety and efficacy of LY2951742, a
`monoclonal antibody to calcitonin gene-related peptide, for the
`prevention of migraine: a phase 2, randomised, double-blind,
`placebo-controlled study,” Lancet Neurol. 13: 885-92 (2014)
`Goldberg, S.W., and Silberstein, S., “Targeting CGRP: A New Era
`for Migraine Treatment,” CNS Drugs 29:443-452 (2015)
`Pellesi, L., et al., “Spotlight on Anti-CGRP Monoclonal Antibodies
`in Migraine: The Clinical Evidence to Date,” Clinical Pharmacology
`in Drug Development 6(6) 534-547 (2017)
`
`- 14 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2164
`
`2165
`
`2166
`
`2167
`
`2168
`
`2169
`
`2170
`
`2171
`
`2172
`
`2173
`
`2174
`
`Description
`Li, Y-J. and Peng, J., “The cardioprotection of calcitonin gene-related
`peptide-mediated preconditioning,” European Journal of
`Pharmacology 442: 173-177 (2002)
`Intentionally left blank
`Lauritsen, C. and Silberstein, S., “Calcitonin Gene-Related Peptide,
`Monoclonal Antibodies, and Migraine,” Practical Neurol. 21-29
`(2016)
`Underwood, E., “A Shot at Migraine,” Science 351(6269): 116-119
`(2016)
`Ajovy (fremanezumab-vfrm) prescribing information (Jan. 2019),
`FDA Label, available at
`https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761089
`s000lbl.pdf (last visited June 28, 2019)
`Maasumi, K., et al., “CGRP and Migraine: The Role of Blocking
`Calcitonin Gene-Related Peptide Ligand and Receptor in the
`Management of Migraine,” Drugs 78: 913-928 (2018)
`Court, E., “New migraine drugs have promise — and a $8,500
`price tag,” Market Watch,
`https://www.marketwatch.com/story/new-migraine-drugs-have-pro
`mise-and-a-8500-price-tag-2017-06-09/print, (last visited May 16,
`2019)
`D’Amico, D. and Tepper, S.J., “Prophylaxis of migraine: general
`principles and patient acceptance,” Neuropsychiatric Disease and
`Treatment 4(6): 1155-1167 (2008)
`Carleton, J., “CGRP Antibodies: A Potential Game Changer in
`Migraine Prevention,” (July 11, 2015), Migraine Disorders,
`https://www.migrainedisorders.org/news-and-updates/blog/cgrp-anti
`bodies-a-potential-game-changer-in-migraine-prevention, (last
`visited March 20, 2019)
`McAllister, P., “Monoclonal Antibodies and Migraine:
`What the Neurologist Needs to Know,” Practical Neurol. 18-22
`(2017)
`Elvidge, S., “Anti-CGRP antibodies for migraine turn
`industry heads,” Nature Biotechnology 32(8): 707 (2014)
`- 15 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2175
`
`2176
`
`2177
`
`2178
`
`2179
`
`2180
`
`2181
`
`2182
`
`Description
`Ning, X., et al., “Long-Term Safety Fremanezumab: Results of a
`1-Year Study,” poster no. P1.015 at The American Academy of
`Neurology 71st Annual Meeting (2019)
`McAllister, P., et al., “Long-Term Impact of Fremanezumab on
`Response Rates, Acute Headache Medication Use, and Disability in
`Patients with Chronic Migraine: Results of 1-Year Study,” poster no.
`P2.015 at The American Academy of Neurology 71st Annual Meeting
`(2019)
`Brandes, J.L., et al., “Long-Term Impact of Fremanezumab on
`Response Rates, Acute Headache Medication Use, and Disability in
`Patients with Episodic Migraine: Results of 1-Year Study,” poster no.
`P1.005 at The American Academy of Neurology 71st Annual Meeting
`(2019)
`Maassen van den Brink, A.M., et al., “Is CGRP Receptor Blockade
`Cardiovascularly Safe? Appropriate Studies are Needed,” Headache
`58(8):1257-1258 (2018)
`Dumas, P., “To People With Migraine – What You Need To Know,”
`(June 28, 2017), Migraine Again,
`https://migraineagain.com/cgrp-medications-migraine/, (last visited
`March 20, 2019)
`Tso, A.R. and Goadsby, P.J., “Anti-CGRP Monoclonal Antibodies:
`the Next Era of Migraine Prevention?,” Curr. Treat. Options Neurol.
`19(27): 1-11 (2017)
`Silberstein, S.D., et al., “The Effect of Beginning Treatment With
`Fremanezumab on Headache and Associated Symptoms in the
`Randomized Phase 2 Study of High Frequency Episodic Migraine:
`Post-Hoc Analyses on the First 3 Weeks of Treatment,” Headache
`59(3): 1-11 (2018)
`Dolgin, E., “Migraine drug race turns its final corner, FDA decisions
`in sight,” Nature Biotechnol. 36(3): 207-208 (2018)
`
`- 16 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2183
`
`2184
`
`2185
`
`2186
`
`2187
`
`2188
`
`2189
`
`2190
`
`2191
`
`2192
`
`Description
`Digre, K., “American Headache Society president: ‘Exciting,
`cautious’ time for patients with migraine,” (October 11, 2018),
`www.healio.com,
`https://www.healio.com/family-medicine/neurology/news/online/%
`7Be3e75c0f-21c7-4de1-a78c-5e3a2f0ba8d6%7D/american-headach
`e-society-president-exciting-cautious-time-for-patients-with-migrain
`e, (last visited March 20, 2019)
`Bigal, M. E., et al., “From LBR‑101 to Fremanezumab for
`Migraine,” CNS Drugs 32:1025-1037 (2018)
`Pietrini, U., et al., “Hypertension in headache patients? A
`clinical study,” Acta Neurol. Scand. 112: 259-264 (2005)
`Cassata, C., “Kristin Chenoweth: Migraine Is More Than a Bad
`Headache,” (April 3, 2019) Healthline,
`https://www.healthline.com/health-news/kristin-chenoweth-on-livin
`g-with-migraines, (last visited March 30, 2019)
`Intentionally left blank
`de Turenne, V., “Game Changer,” UCLA Health,
`https://www.uclahealth.org/u-magazine/game-changer-1741, (last
`visited May 20, 2019)
`Bender, K., “Promise and Pitfalls of Preventing
`Migraine With CGRP Inhibitors,” (July 10, 2018), MD Magazine,
`https://www.mdmag.com/journals/md-magazine-neurology/2018/jul
`y-neuro-2018/promise-and-pitfalls-of-preventing-migraine-with-cgr
`p-inhibitors, (last visited March 20, 2019)
`Silberstein, S.D., “Preventive Migraine Treatment,” Continuum
`(Minneap. Minn.) 21(4):973-989 (2015)
`Transcript from the Deposition of Alain P. Vasserot, Ph.D., Case
`IPR2018-01422, IPR2018-01423, IPR2018-01424, IPR2018-01425,
`IPR2018-01426 and IPR2018-01427 (May 1, 2019)
`Transcript of Andrew C. Charles, M.D., Case IPR2018-01422,
`IPR2018-01423, IPR2018-01424, IPR2018-01425, IPR2018-01426
`and IPR2018-01427 (May 3, 2019)
`
`- 17 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2193
`
`2194
`
`2195
`
`2196
`
`2197
`
`2198
`
`2199
`
`2200
`
`2201
`
`Description
`Prudenzano, M.P., et al., “The comorbidity of migraine and
`hypertension. A study in a tertiary care headache centre,” J.
`Headache Pain 6(4): 220-222 (2005)
`Scher, A. I., et al., “Comorbidity of migraine,” Curr. Opin. Neurol.
`18(3): 305-310 (2005)
`Chaverneff, F., “Fremanezumab May Help Reduce Medication
`Overuse in Chronic Migraine,” (July 1, 2018), Neurology Advisor,
`https://www.neurologyadvisor.com/conference-highlights/ahs-2018/
`fremanezumab-may-help-reduce-medication-overuse-in-chronic-mi
`graine/, (last visited May 21, 2019)
`Mavridis, T., et al., “Anti-Calcitonin Gene-Related Peptide
`Monoclonal Antibodies: Adverse Effects. What Do We Really
`Know? A Literature Review,” EMJ Innov. 3(1): 64-72 (2019)
`Buhlmann, N., et al., “A Receptor Activity Modifying Protein
`(RAMP)2-Dependent Adrenomedullin Receptor Is a Calcitonin
`Gene-Related Peptide Receptor when Coexpressed with
`Human RAMP1,” Endocrinology 140(6): 2883-2890 (1999)
`Fraser, N. J., et al., “The Amino Terminus of Receptor Activity
`Modifying Proteins Is a Critical Determinant of Glycosylation State
`and Ligand Binding of Calcitonin Receptor-Like Receptor,”
`Molecular Pharmacology, 55(6): 1054-1059 (1998)
`Marquez de Prado, B. and Russo, A.F., “CGRP receptor antagonists:
`A new frontier of anti-migraine medications,” Drug Discovery Today
`3(4): 593-597 (2006)
`Allen, D.B., “Limitations of short-term studies in predicting
`long-term adverse effects of inhaled corticosteroids,” Allergy 54:
`29-34 (1999)
`International Conference on Harmonisation of Technical
`Requirements for Registration of Pharmaceuticals for Human Use,
`“ICH Harmonised Tripartite Guideline: The extent of population
`exposure to assess clinical safety for drugs intended for long-term
`treatment of non-life-threatening conditions” (October 1994)
`
`- 18 -
`
`
`
`Case IPR2018-01710
`Patent No. 8,586,045
`
`
`Exhibit #
`
`2202
`
`2203
`
`2204
`
`2205
`
`2206
`
`2207
`
`2208
`
`2209
`
`2210
`2211
`2212
`2213
`2214
`
`Description
`“Teva Announces U.S. Approval of
`AJOVY (fremanezumab-vfrm) Injection, the First and
`Only Anti-CGRP Treatment with Both Quarterly and
`Monthly Dosing for the Preventive Treatment of Migraine
`in Adults,” BusinessWire,
`https://www.businesswire.com/news/home/20180914005613/en